Hong Kong Stock Movement: INNOGEN-B surged 36.63%, with clear capital flow; what risks are hidden behind the rising market sentiment?

Hong Kong Stock Movement INNOGEN-B surged 36.63%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry PAG Biopharma-B rose 5.70%, with a trading volume of HKD 411 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics rose 0.62%. Based on recent key news: On May 18, Innovent Biologics announced the latest R&D progress, focusing on drug production for tumors, cardiovascular, and metabolic diseases. This news boosted market confidence in its future growth, driving the stock price up. Source: PR Newswire On May 19, Innovent Biologics issued a forward-looking statement, emphasizing that future business changes may lead to actual results differing from expectations. Nevertheless, the market remains optimistic about its robust R&D capabilities, and the stock price continued to rise. Source: Innovent Biologics On May 19, Innovent Biologics released original content through PR Newswire, further consolidating its leading position in the biopharmaceutical field and attracting investor attention. Source: Public Technologies The biopharmaceutical industry has recently performed strongly, with significant capital inflow. Kangfang Biologics fell 0.62%, with a trading volume of HKD 240 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene rose 1.03%. Based on recent key news: On May 14, BeiGene announced that BRUKINSA® received FDA accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. This is the first new BCL2 inhibitor approved in the U.S. in ten years, driving the stock price up. On May 11, Citigroup released the latest research report, stating that BeiGene's Q1 performance was strong, with total revenue exceeding estimates by 5%, and raised its full-year revenue guidance, maintaining a "Buy" rating and further increasing the target price for U.S. stocks to $453. On May 18, BeiGene's Tislelizumab in the solid tumor field and other early pipelines provided another growth curve for the company, enhancing market confidence. The global pharmaceutical industry is becoming increasingly competitive, and the breadth and advancement speed of innovative drug pipelines are key